Julie Totten

Julie Totten is Managing Director of Junction Market Access, an independent consultancy specializing in end-to-end market access support and value communications.  She is a respected leader in the biopharmaceutical sector, with over 25 years of executive experience across regulatory affairs, market access, patient advocacy and government relations. Prior to embarking on consulting, Julie built out the market access and government relations function at both Ultragenyx Canada and Intercept Pharma Canada and held senior level regulatory and market access roles at Gilead Sciences Canada.

Julie brings a unique understanding of the Canadian regulatory, reimbursement and policy environment and is known for her ability to collaborate across stakeholders to effectively deliver regulatory approvals, positive HTA recommendations, successful PCPA negotiations and formulary listings. She has experience across a wide array of therapeutic areas with specialized experience in rare and ultra-rare disease.

She has served on several BIOTECanada and RAREi policy committees and is a board member of the Canadian Primary Biliary Cholangitis Society.